drugset / Trial / NCT02070705
DCE MRI in Patients With Pancreatic Cancer
Terminated
77 enrolled
OHSU Knight Cancer Institute
National Cancer Institute (NCI) · collabNational Institute for Biomedical Imaging and Bioengineering (NIBIB) · collabNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collabOregon Health and Science University · collab
Non-randomizedParallel-groupSingle-blindDiagnostic
Summary
This clinical trial studies an imaging technique known as dynamic contrast enhanced magnetic resonance imaging (DCE MRI) in identifying the presence of pancreatic cancer. DCE MRI is a procedure that takes detailed pictures of functional and structural properties inside the body using magnetic field imaging. These images may better characterize pancreatic cancer in patients at high risk or in patients who may have undergone chemotherapy for pancreatic cancer.
Timeline
- Start
- 2014-01-31
- Primary completion
- 2024-08-07
- Completion
- 2024-08-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Ferumoxytol | Diagnostic / imaging agent | — | Intravenous |